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Abstract
Objective—Pulmonary embolism (PE) can cause intracardiac hemolysis and increased plasma 
hemoglobin and arginase-1, which can worsen pulmonary vasoconstriction. We test the hypothesis 
that patients with PE that causes tricuspid regurgitation (TR), indicative of higher pulmonary 
arterial pressures, have decreased leukocyte expression of hmox-1 compared with patients with PE 
and no TR and patients without PE.
Design—Prospective, noninterventional study.
Patients—Normotensive patients with suspected PE (n=87) who underwent CT pulmonary 
angiography and transthoracic Doppler-echocardiography.
Measurements—Significant TR was defined as a jet velocity > 2.7m/s. Leukocyte expression of 
hmox-1, haptoglobin, haptoglobin related gene, the haptoglobin receptor, CD163 and cox-2 genes 
were assessed by quantitative rtPCR, and the hmox-1 promoter was examined for the −413 A→T 
SNP and GT repeat polymorphisms.
Results—Of the 44 (50%) with PE+, 22 had TR+, and their mean pulmonary vascular occlusion 
(39±32%) did not differ significantly from patients who were TR− (28±26%, P=0.15). Patients 
with PE+ and TR+ had significantly lower expression of hmox-1 and haptoglobin genes than 
patients without PE+ and no TR. Expression of hmox-1 varied inversely with TR velocity 
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(r2=0.45, P<0.001) for PE+ (n=22) but not patients without PE. Hmox-1 expression did not vary 
significantly with genotype. Cox-2 did not differ between groups and had no correlation with TR.
Conclusions—Severity of TR varied inversely with hmox-1 expression, suggesting that hmox-1 
expression affects pulmonary vascular reactivity after PE.
Graphical Abstract
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Introduction
Acute pulmonary embolism (PE) causes obstruction of the pulmonary arteries, leading to 
aberrant flow within the pulmonary arterial tree. With more severe PE, the pulmonary 
arterial pressure increases, leading to turbulent blood flow within the right ventricle from 
regurgitation across the tricuspid and pulmonary valves, as well as increased shear forces 
exerted on erythrocytes within the pulmonary arteries.[1-5] The degree of pulmonary 
hypertension correlates poorly with the percentage pulmonary vascular obstruction produced 
by thrombus, suggesting variable effect of PE on the soluble determinants of the pulmonary 
arteriolar constrictor-dilator tone.[6-9] The potent vasodilator, nitric oxide (NO), produced 
tonically by vascular endothelial nitric oxide synthase (eNOS), plays a pivotal role in 
maintaining normal pulmonary vascular resistance under these conditions.[10] Thus, it can 
be hypothesized that different patients with PE causing the same degree of pulmonary 
vascular obstruction may manifest widely different pulmonary arterial resistances, 
depending in part upon the balance of their pulmonary arterial vasoconstrictor-dilator 
phenotype, which in turn, depends upon NO availability.
Intravascular hemolysis liberates hemoglobin and diffusible heme, which both directly bind 
NO, and arginase-1, which cleaves the eNOS substrate, L-arginine.[11,12] Prior work has 
found evidence of hemolysis with PE, shown by a severity-dependent reduction in serum 
haptoglobin in animals and humans with acute PE.[1,2,13] Humans with severe PE have 
increased arginase-1 and decreased plasma L-arginine concentrations.[14] These data 
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suggest that the cognate ability of haptoglobin to sequester hemoglobin, and thus limit its 
vasoconstrictive effect, provides a protective effect—a finding already observed in humans 
with sepsis and subarachnoid hemorrhage.[15,16] Similarly, inducible heme oxygenase-1 
(hmox-1) converts free heme from a potent vasoconstrictor, oxidant and inflammatory 
molecule into the vasodilator carbon monoxide and the antioxidant biliverdin, possibly 
explaining elevations in carboxyhemoglobin concentrations observed in nonsmoking 
patients with PE.[17] Experimentally increased expression of heme oxygenase-1 improves, 
and decreased expression worsens right heart injury in experimental models of pulmonary 
hypertension.[18-20]
We hypothesize an overarching cause-effect relationship, such that patients who have poor 
ability to induce hmox-1, have impaired ability to control the vasoconstrictive response to 
PE, and therefore have higher pulmonary arterial pressures. In this report, we test the 
specific hypotheses that patients with severe PE (1) express hmox-1 transcripts in peripheral 
leukocytes that is inversely proportional to the velocity of the regurgitant jet observed across 
the tricuspid valve on Doppler-echocardiography, and (2) exhibit lower hmox-1 expression, 
compared with patients who have minor PE (defined by the degree of TR) as well as patients 
without PE.
Methods
Study Design
This was a secondary analysis of a four center prospective study of diagnostic accuracy 
conducted in patients with suspected PE (NCT00368836), which includes patients who were 
ultimately diagnosed with PE (PE+) or had PE excluded (PE−).[21] The criterion standard 
for PE was from multidetector-channel computerized tomographic pulmonary angiography 
(CTPA) obtained on the day of enrollment.[22] Images were obtained at each site as part of 
standard care, and were done on 64 slice multi-detector equipment with ≤2.5mm 
collimation. Intravenous contrast media was given to all patients according to local protocol 
using a computer-controlled mechanized timing injector in all cases. Images were obtained 
using energy, pitch, rotation settings as required for the patient's body habitus. All patients 
had reconstructions that included transverse, coronal and saggital views. Acute PE was 
considered present if two independent board certified radiologists interpreted a filling defect 
consistent with acute PE in the absence of changes associated with chronic PE (e.g., 
webbing). All scans read as positive for PE were further evaluated for the location of the 
filling defect and the percentage obstruction of the vessel(s) using an explicit data collection 
format to facilitate computation of the percentage of total pulmonary vascular occlusion 
using the method of Mastora et al.[23] Patients underwent transthoracic echocardiography as 
part of standard care within 24 h. Echocardiography was performed using techniques as 
previously described, including pulse wave Doppler interrogation of the TR jet velocity 
measured >2.7 m/S, corresponding to an estimated right ventricular systolic pressure of 40 
mm Hg, which is elevated at all patient ages.[3]
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Blood collection
All patients had blood drawn within 12 hours of CTPA scanning. Blood was drawn by a 
qualified phlebotomist using 18 gauge needles into two (blue-top) tubes containing sodium 
citrate dihydrate to yield a final concentration of citrate in plasma equal to 0.11mM (3.2%) 
and 6 mL of whole blood was instilled into a Paxgene® Blood RNA tube (QIAGEN USA), 
which was left at room temperature for 24 hours and then frozen at −20°C. Plasma samples 
were drawn and transported on ice and immediately centrifuged at 2500g × 15 minutes and 
the plasma fraction separated from red cell mass. Plasma was stored at −80°C.[24]
Measurements
RNA was isolated from peripheral leukocytes using the PAXgene blood RNA kit (Qiagen, 
Valencia, CA) according to the manufacturer's protocol. First-strand complementary DNA 
was synthesized using iScript™ cDNA systhesis kit (Bio-Rad, Hercules, CA, USA). The 
reverse transcription reaction was incubated at 42°C for 30 minutes and stopped by heating 
to 85°C for 5 minutes. 50 ng of final product was used as template for PCR. qRT-PCR was 
performed using TaqMan® Probe-Based Detection (Applied Biosystems, Foster City, CA, 
USA) per the manufacturer's instructions with an ABI Prism 7000 Sequence Detection 
System using Taqman® gene expression assays (Applied Biosystems) and Taqman® Gene 
expression master mix (Applied Biosystems). Template was amplified by 40 cycles of 
denaturation at 95°C for 15 seconds, annealing of primers and probe together with extension 
at 60°C for 1 minute in duplicate reactions. Fluorescence data were acquired during a 
combined anneal / extension step. RT negative reactions were run on each plate to confirm 
the absence of DNA contamination. Fold change values were calculated using comparative 
Ct analysis and normalized to those of 18s rRNA, which was an invariant.[25] We examined 
expression of hmox-1 (Assay ID = Hs01110251_m1), CD-163 (Assay ID = 
Hs01016663_m1), haptoglobin (Assay ID = Hs00978377_m1), haptoglobin related protein 
(Assay ID = Hs00750565_s1) because of their essential roles in the disposition of free 
plasma hemoglobin. We also measured cyclooxygenase-2 transcripts (Assay ID = 
Hs01573469_m1) in view of this enzyme's role in producing vasoactive prostaglandins. 
Recognizing the role of two major genotypes that affect hmox-1 expression as a potential 
confounder, we performed genotyping at the −413 A→T single nucleotide polymorphism 
and measured the length of (GT)n repeats in the hmox-1 promoter.[26,27] The hmox-1 −413 
(A→T) polymorphism was assessed with a TaqMan 5’-allele discrimination assay (Custom 
TaqMan SNP Genotyping Assay; Applied Biosystems, Foster City, CA, USA). The primer 
sequences used were from Rueda et al (2007): 5’-GGG-TTG-CTA-AGT-TCC-TGA-TGT-
TG-3 (forward) and 5’-CCC-AGA-AGG-TTC-CAG-AAA-GCT-3 (reverse), and the 
TaqMan minor groove binder probe sequences were 5’-ACC-AGG-CTT-TTG-CTC-T-3 
AND 5’-ACC-AGG-CTA-TTG-CTC-T-3; the probes were labeled with the fluorescent dyes 
FAM and VIC, respectively. The real-time PCR reaction was performed in a total reaction 
volume of 20 μl with 20ng DNA, with the following amplification protocol: initial 
denaturation at 95°C for 10 minutes, followed by 40 cycles of denaturation at 95°C for 15 
seconds and annealing and extension at 60°C for 1 minute on the ABI7500Fast (Applied 
Biosystems). After PCR, the genotype of each sample was attributed automatically by 
measuring the allele-specific fluorescence with the ABI7500 Software v.2.0.1 for allelic 
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discrimination (Applied Biosystems). Samples were run in duplicate reactions. Positive 
controls, confirmed by sequencing, for all three genotypes (AA, AT, TT) were included on 
each plate.
Determination of variable length polymorphism (GT)n fragment lengths in the HMOX1 
promoter was performed by polymerase chain reaction (PCR) and subsequent sizing using 
capillary electrophoresis. Specific primers used (forward: 5’- AGA GCC TGC AGC TTC 
TCA GA’- 3’, modified with a 5’-FAM label, and reverse: 5’- ACA AAG TCT GGC CAT 
AGG AC’3’), (Integrated DNA Technologies, Coralville, IA), were previously designed by 
Exner et al.[28] PCR amplification was performed in 15 μl reactions which consisted of 100 
ng of template DNA, 0.5 μl 5 μM forward and reverse primer, 1.5 μl 250 μM dNTP, 1.5 μl 
10X Buffer, 1.5 μl 25 mM MgCl2, 0.12 μl of Amplitaq Gold DNA Polymerase (Applied 
Biosystems, Foster City, CA), and 8.18 μl of double distilled water. All PCR reactions were 
performed in an Applied Biosystems 2720 Thermal Cycler, programmed for an initial 
denaturation at 95°C for 5 minutes, followed by 30 cycles at 95°C for 30 s, 58°C for 30 s, 
and 720C for 30s, with a final extension at 72°C for 7 minutes. Subsequently, 1 μl of PCR 
product was added to 12 μl of HiDi Formamide and 0.5 μl of Genescan 500 LIZ standard 
(both from Applied Biosystems). Capillary electrophoresis-based DNA sizing was 
performed on an ABI 310 DNA genetic analyzer (Applied Biosytems). The resultant 
electropherograms were analyzed using Genemapper v4.0 genotyping software (Applied 
Biosystems). (GT) n was determined based on the differential mobility of amplicons with 
different sizes. The repeat numbers were calculated using the amplicon size and the 
sequencing reading of the reference samples. All samples were run in duplicate. Select 
samples from each category were chosen to be confirmed by DNA capillary sequencing, 
which accurately verified the size determined by the fragment analysis. GT repeats on HO-1 
alleles were classified as follows: short (<26), medium 26-30, or large (>30).
Biomarkers of hemolysis
Arginase-1 and hemoglobin were measured using commercially available enzyme-linked 
immunoabsorbant assays (Human Arginase-1 I ELISA kit, Cat No: HK322. Hycult Biotech, 
Plymouth Meeting, PA; Human Hemoglobin ELISA kit, Cat No: E88-135, Manufacturer: 
Bethyl Laboratories, Montgomery, TX). Plasma D-dimer and fibrinogen concentrations 
were measured in batches of single-freeze-thawed aliquots of plasma on FDA-cleared 
devices (VIDAS ELISA, bioMerieux, Durham NC, Dade® Thrombin Reagent, Dade 
Behring, Inc. Newark, DE).
Statistical analysis
Continuous data were examined with the Shapiro-Wilk test and P<0.1 used to reject the 
hypothesis of a normal distribution; non-normal data are presented as medians and 
interquartile ranges (IQR). Parametric and categorical baseline data were compared with an 
unpaired t-test or a Chi-square statistic, respectively with 2 sided p values reported. 
Correlation was examined with first-order regression. Between-group and paired medians 
were compared for non-normal data using the the Kruskal-Wallis test with pairwise 
comparisons. P<0.05 was considered significant. All statistical testing was performed on 
StatsDirect (Cheshire, England, v 2.6.2).
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Results
The study population included 109 patients with PE, including 44 with PE causing a mean 
pulmonary vascular obstruction of 33±28% and 65 without PE, (PE−). Doppler assessment 
found an abnormally high TR jet velocity (>2.7 m/S) in 20/44 patients (45%) with PE (PE
+TR+) versus 29/65 (44%) of PE− patients.The mean pulmonary vascular occlusion of TR+ 
patients (39±32%) did not differ significantly from patients who were TR− (28±26%, 
P=0.15). The mean estimated right ventricular pressure in the PE+TR+ group was 49±14 
mm Hg, which was not significantly different from the mean right ventricular systolic 
pressure of the 29 PE− patients who had TR jet velocity>2.7 m/S (50±15 mm Hg, P=0.55, 
unpaired t-test). Patients with PE+TR+ did not have a significantly different mean 
pulmonary vascular obstruction than patients who had PE and no TR (PE+TR−). Table 1 
shows the clinical features of patients divided by PE status, and demonstrates that patients 
with PE were similar in terms of age and comorbidities compared with patients who did not 
have PE.
Table 2 shows the fold change in gene expression based upon presence or absence of PE and 
significant TR relative to the housekeeper 18S RNA for hmox-1, haptoglobin receptor, 
CD163, haptoglobin, haptoglobin related protein and cyclooxygenase-2. Medians are shown 
because the data were not normally distributed. The median values and associated 
interquartile ranges for hmox-1 and haptoglobin show that patients with PE+TR+ had lower 
expression of these genes compared with patients who were PE+TR− or PE−. To explore 
this potential relationship further, Figures 2A and 2B plot the first order regression line of 
the fold change in hmox-1 versus the TR jet velocity. The results demonstrate a significant 
inverse relationship for patients with PE (r2,=0.45, P<0.001) but this inverse relationship 
was absent in patients without acute PE (r2,=0.001, P=0.52). The cyclooxygenase-2 gene 
was not significantly different between groups and had no correlation with the TR jet 
velocity in patients with PE (R2=0.03). These data suggest an hmox-1 specific 
transcriptional difference in the way that patients with PE adapt to increased right heart 
pressure compared with patients who have TR from non thrombotic causes.
Table 3 shows a significant increase in the median value for the plasma biomarker of 
hemolysis, arginase-1 in patients with PE+TR+ by pairwise comparison using the Kruskal-
Wallis test. This finding is consistent with previous work has found that arginase-1 elevated 
in acute PE.[14,29] Cell-free hemoglobin, D-dimer and fibrinogen median concentrations 
were not different between groups.
Table 4 is a matrix that shows distribution of hmox-1 genotypes for the −413 A→T sequence 
variation and for the GT repeats in the promoter region and the median fold change in 
expression associated with the genotype. The range of the median fold change in hmox-1 
expression was 0.34 to 1.89 and neither genotype was more frequent among patients with 
PE and significant TR. These data indicate at most a mild effect of genotype on hmox-1 
expression in this patient sample. The results also suggest that other still unknown inherited 
or acquired factors may influence expression of hmox-1.
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DISCUSSION
This study documents an inverse relationship between leukocyte hmox-1 expression in 
patients with PE and the severity of pulmonary hypertension, as assessed by degree of TR, 
and lower hmox-1 and haptoglobin expression in patients with more severe PE compared 
with patients with PE and no TR, and patients without PE. The patients without PE included 
44% with significant TR, suggesting evidence of pulmonary hypertension from non-
thrombotic causes. Patients with PE were well matched in terms of age and comorbidities to 
patients without PE. The inverse correlation between hmox-1 expression in circulating 
leukocytes and the TR jet velocity in patients with acute PE was significant (r2=0.45, p 
<0.001), but this significance was absent in patients without PE (r2=0.01, P=0.52). The 
magnitude of hmox-1 expression varied minimally with variations in the hmox-1 promotor 
(−413 (A→T) polymorphism or GT repeats), providing evidence that the reduced hmox-1 
expression with severe PE was not a result of either of these genotypes. Taken together, 
these data support the hypothesis that the heme oxygenase-1 enzyme has a role in 
determining the natural history of pulmonary hypertensive response to acute PE. We believe 
that heme oxygenase helps to mitigate a secondary pulmonary vasoconstriction observed 
with acute thrombotic PE that results from intracardiac hemolysis, possibly related to shear 
stresses on the erythrocyte.[1,2,13,14] We found no significant difference in expression of 
the inducible cyclooxygenase-2 enzyme, which synthesizes both vasodilatory and 
vasoconstrictive prostaglandins in the setting of PE.[9] This finding suggests a more specific 
adaptive role of increasing leukocyte hemeoxygenase-1 transcripts. A large body of 
literature has implicated hemolysis as a cause of chronic pulmonary hypertension in 
hemoglobinopathies, primarily sickle cell disease, but this is the first report of evidence 
linking hemolysis with acute pulmonary hypertension from thrombotic PE in humans.[30]
We hypothesize acute moderate to severe PE causes turbulent flow across the tricuspid and 
pulmonic valves and in the pulmonary tree, causing rupture of a small percentage of red 
cells in or immediately proximal to or within the pulmonary vascular tree. This timing and 
location of this shear effect requires release of a only a small amount of free hemoglobin to 
have a profound effect on pulmonary vascular tone. Upon their rupture, erythrocytes release 
tetrameric (α2β2) hemoglobin, which can avidly bind NO, but must first dissociate into αβ 
dimers before haptoglobin can bind them with high avidity and inactivate this NO 
scavenging effect.[31] In contrast to the millimolar concentrations required to constrict 
peripheral vasculature, free hemoglobin in the low micromolar concentration will 
significantly increase pulmonary vascular resistance. [32,33] Thus, any free hemoglobin 
produced in the right ventricle occurs at a highly vulnerable time and place for a patient with 
large clots that are mechanically obstructing the pulmonary arteries. The pulmonary 
vasoconstrictive effect of hemolysate has been well documented in isolated lung 
preparations.[1,34] Release of hemoglobin (and ultimately heme), and arginase-1 into the 
plasma results in binding of nitric oxide and also reduction in L-arginine, respectively, 
causing a relative reduction in vasodilatory effect.[14,29] At the same time, acute PE can 
increase concentrations of vasoconstrictive molecules in the pulmonary vascular tree, 
resulting in a shift toward vasoconstriction. [7-9] In this scenario, the efficiency with which 
cells in the blood and lung can remove the constrictor effect of heme via haptoglobin and 
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heme oxygenase-1, and maintain tonic de novo nitric oxide synthesis via eNOS should have 
a pivotal role in this balance.
Strengths of the study include the relatively large number of patients examined for both 
hmox-1 mRNA and DNA sequencing for the two most common genotypes known to 
decrease its expression. We believe our data provide useful evidence that neither the −413 
A→T single nucleotide polymorphism nor the length of (GT)n repeats in the hmox-1 
promoter play a clinically significant role in hmox-1 expression in patients with PE. Also 
blood was drawn within 12 hours of PE diagnosis or exclusion, and therefore captured 
hmox-1 transcripts in the acute setting. This is important because the patient's clinical 
condition can change with time and treatments, which may also affect the steady state of 
mRNA content in peripheral leukocytes.
Limitations of present work include that the blood samples drawn from an antecubital vein 
probably do not contain the same concentration of plasma free hemoglobin and heme that is 
released in the right heart and pulmonary vascular tree with severe PE. We examined 
circulating leukocytes because of their convenience, but also because these cells are likely to 
be the first cells to contact molecules released from ruptured erythrocytes, and their 
genotype, assessed by mRNA content, and should provide insight into the magnitude of 
effect of hemolysis. However, this approach precludes ability to determine which leukocyte 
is responsible for the change in expression. We also did not examine haptoglobin phenotype, 
which may affect ability of haptoglobin to scavenge hemoglobin.[31] Additionally, the clot 
burden tended to be higher in TR+ patients (P=0.15), suggesting that clot severity as a 
possible source of bias. However, preclinical and clinical data support the hypothesis that 
impared hmox-1 activity may increase the initial embolic load and reduce endogenous rate 
of resolution.[35,36]
In conclusion, this report presents the first published data from humans to show an inverse 
correlation between the steady-state level of leukocyte hmox-1 transcripts and the estimated 
degree of TR in patients. This is consistent with our previous publications showing an 
increase in circulating arginase-1 and a simultaneous, but transient reduction in plasma L-
arginine in patients and animals with PE.[14,29] The data suggest that haptoglobin and heme 
oxygenase-1 expression have important modulatory roles in the development of acute 
pulmonary hypertension in patients with PE.
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CT computerized tomography
CTPA CT pulmonary angiography
CTEPH Chronic thromboembolic pulmonary hypertension
eNOS endothelial cell derived nitric oxide synthase
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NO nitric oxide
PE pulmonary embolism
RV right ventricle
SBP systolic blood pressure
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Highlights
Severe acute pulmonary embolism (PE) causes intravascular hemolysis
Hemolysis releases free hemoglobin and heme, which scavenge nitric oxide
Induction of hmox-1 may be beneficial as it detoxifies heme
hmox-1 transcripts were inversely proportional to right ventricular pressure
Leukocyte expression of hmox-1 may be an adaptive response to PE
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Figure 1. 
Flow diagram of patients with complete data including echocardiography.
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Figure 2. 
First order regression plots of the TR jet velocity, estimated by Doppler echocardiography 
versus fold expression of hmox-1 relative to 18S RNA. A. Patients with acute PE, B. 
Patients with PE excluded.
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Table 1
Clinical characteristics of the first study population
Table 1 PE+ N=44 PE− N= 65
P*
Vital signs and demographics Mean or N Standard deviation or % Mean or N Standard deviation or %
Age, years 50 16 58 18 0.07
Body Mass Index 31.9 8.2 28.9 7.6 0.16
SaO2, % 97 2 97 2 0.90
Systolic blood pressure, mm Hg 116 13 135 18 <0.001
Heart Rate, beats/min 94 21 89 18 0.46
Caucasian race 20 45% 44 68% 0.02
Black race 16 36% 18 28% 0.34
Female gender 26 59% 34 52% 0.48
Symptoms
Syncope 2 5% 2 3% 0.69
Pleuritic chest pain 20 48% 17 26% 0.04
Dyspnea 25 56% 35 54% 0.76
Hemoptysis 0 0% 2 3% 0.24
Cough 11 25% 27 42% 0.08
Limb swelling 10 23% 8 12% 0.15
Risk Factors**
Prior stroke 0 0% 2 3% 0.24
Recent surgery 6 14% 10 15% 0.80
Heart failure 4 9% 8 12% 0.60
Bed rest >72h 10 23% 15 23% 0.97
Prior DVT without PE 8 18% 7 10% 0.27
Active connective tissue disease 1 2% 6 9% 0.15
Known thrombophilia 1 2% 0 0% 0.22
Active malignancy 5 11% 6 9% 0.72
Sickle cell disease 0 0% 1 2% 0.41
Anemia 3 7% 5 8% 0.86
Diabetes 4 9% 13 20% 0.12
Focal Infection 0 0% 5 8% 0.06
Current estrogen use 6 13% 3 5% 0.09
History of COPD 1 2% 6 9% 0.15
History of Asthma 5 12% 13 20% 0.23
Never smoked 30 68% 47 72% 0.64
Aspirin use in past 7 days 19 43% 27 42% 0.86
*
P values from unpaired t-test or Chi-Square
**
Prior history requiring treatment; reported by patient or from documented past medical history at time of diagnosis
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